Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Protalex announces preliminary unblinded findings from Cohorts 1-4 of U.S. Phase 1b Trial of PRTX-100 in active Rheumatoid Arthritis Patients


Tuesday, 3 Jun 2014 08:00am EDT 

Protalex Inc:Completes analysis of certain key parameters from its U.S.-based multicenter Phase 1b randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (RA) (PRTX-100-104 Study).Primary endpoint is to assess safety and tolerability, with secondary objectives to examine the effects of PRTX-100 on measures of disease activity.Preliminary results indicated that PRTX-100 was generally safe and well tolerated and the Adverse Event (AE) profile was consistent with prior trials results.Study revealed positive effects of PRTX-100 treatment on certain measures of disease activity, although these effects were not statistically significant. 

Company Quote

5.75
-0.25 -4.17%
17 Dec 2014